AAA817

AAA817 is a radioligand therapy developed by Novartis Pharmaceuticals. Its target is PSMA (the sponsor names PSMA). The sponsor states: Inside the body, AAA817 ([225Ac]Ac-PSMA-617) attaches to PSMA on the surface of prostate cancer cells and emits radiation to kill them; this treatment is also called a radioligand therapy. ClinicalTrials.gov describes the intervention as: AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06855277 (Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC) and NCT06780670 (Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy), in prostate cancer. The largest, NCT06855277, plans to enrol 940 participants with primary completion expected 2028-09-29. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.